Comprehensive Review of Serous Tumors of Tubo-Ovarian Origin: Clinical Behavior, Pathological Correlation, Current Molecular Updates, and Imaging Manifestations

Curr Probl Diagn Radiol. 2023 Sep-Oct;52(5):425-438. doi: 10.1067/j.cpradiol.2023.05.010. Epub 2023 May 14.

Abstract

Ovarian cancer is the eighth most common women's cancer worldwide, with the highest mortality rate of any gynecologic malignancy. On a global scale, the World Health Organization (WHO) reports that ovarian cancer has approximately 225,000 new cases every year with approximately 145,000 deaths. According to the National Institute of Health, Surveillance Epidemiology and End Results program (SEER) database, 5-year survival for women with ovarian cancer in the United States is 49.1%. High-grade serous ovarian carcinoma typically presents at an advanced stage and accounts for the majority of these cancer deaths. Given their prevalence and the lack of a reliable method for screening, early and reliable diagnosis of serous cancers is of paramount importance. Early differentiation of borderline, low and high-grade lesions can assist in surgical planning and support challenging intraoperative diagnoses. The objective of this article is to provide a review of the pathogenesis, diagnosis, and treatment of serous ovarian tumors, with a specific focus on the imaging characteristics that help to preoperatively differentiate borderline, low-grade, and high-grade serous ovarian lesions.

Publication types

  • Review

MeSH terms

  • Cystadenocarcinoma, Serous* / pathology
  • Cystadenocarcinoma, Serous* / surgery
  • Female
  • Humans
  • Neoplasm Staging
  • Ovarian Cysts* / pathology
  • Ovarian Neoplasms* / diagnostic imaging
  • Ovarian Neoplasms* / pathology